HUTCHMED (LON:HCM) Sets New 52-Week Low – Here’s What Happened
by Doug Wharley · The Cerbat GemHUTCHMED (China) Limited (LON:HCM – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 182 and last traded at GBX 182, with a volume of 13008 shares. The stock had previously closed at GBX 191.30.
HUTCHMED Stock Performance
The stock has a 50 day moving average of GBX 208.06 and a 200 day moving average of GBX 213.46. The company has a quick ratio of 2.97, a current ratio of 4.96 and a debt-to-equity ratio of 7.91. The company has a market capitalization of £1.56 billion, a price-to-earnings ratio of 3.42 and a beta of 0.45.
About HUTCHMED
We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.
We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.
HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).